New York – Johnson & Johnson has agreed to pay New York $ 230 million to resolve allegations that pharmaceutical giants have contributed to the opioid crisis, Attorney General Letitia James said Saturday. ..
The drug company also agreed to permanently end the production and distribution of opioids in New York and other countries, James said in a statement announcing the settlement.
“We helped the fire, but today they promise to quit their opioid business, not just in New York,” she said.
The proceedings, including the proceedings filed by James in 2019, will remove Johnson & Johnson from the trial scheduled to begin in Long Island next week. This is part of a number of epidemic proceedings that have killed nearly 500,000 people in the last two decades.
Johnson & Johnson downplayed the Attorney General’s announcement in his own statement on Saturday. The settlement includes two prescription painkillers that have been developed by a subsidiary and account for less than 1% of the market and are no longer sold in the United States.
“We do not admit any liability or misconduct by the company,” said Johnson & Johnson, adding that “actions related to the marketing and promotion of critical prescription analgesics are appropriate and responsible.” ..
The settlement was the latest development in the complex world of opioid proceedings across the United States compared to multilateral proceedings against tobacco companies in the 1990s. This reflects the path that some major pharmaceutical companies consider settling in their best interests.
Johnson & Johnson, along with distributors AmerisourceBergen, Cardinal Health and McKesson, announced last year that it would provide a total of $ 26 billion over 18 years to resolve all the cases it faces and use that money to mitigate the crisis.
Copyright 2021 AP communication. all rights reserved. This material may not be published, broadcast, rewritten, or redistributed without permission.
J & J agrees to pay $ 230 million to resolve New York opioid claims
Source link J & J agrees to pay $ 230 million to resolve New York opioid claims